Somewhat Favorable News Coverage Somewhat Unlikely to Impact DURECT Corporation (DRRX) Stock Price
Media stories about DURECT Corporation (NASDAQ:DRRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DURECT Corporation earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 47.3648921199679 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- DURECT Corp (DRRX) Needle Moving -1.25% – Sparta Review (spartareview.com)
- Cheap Stock Alert on DURECT Corporation (NASDAQ:DRRX) – FLBC News (flbcnews.com)
- Oilwell Varco, Inc. (NOV) Increases Again; Strong Momentum for Buyers (techkenyot.com)
- Oilwell Varco, Given $39.10 Consensus PT from Analysts (topactu.net)
DURECT Corporation (NASDAQ DRRX) opened at 1.59 on Friday. The company’s market capitalization is $233.73 million. DURECT Corporation has a 1-year low of $0.74 and a 1-year high of $1.90. The firm has a 50 day moving average of $1.70 and a 200-day moving average of $1.27.
DURECT Corporation (NASDAQ:DRRX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.02. The company had revenue of $4.32 million for the quarter, compared to analysts’ expectations of $5.17 million. DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. On average, equities research analysts anticipate that DURECT Corporation will post ($0.21) earnings per share for the current fiscal year.
A number of research firms have weighed in on DRRX. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of DURECT Corporation in a research note on Monday, May 22nd. Stifel Nicolaus raised shares of DURECT Corporation from a “hold” rating to a “buy” rating and raised their price objective for the company from $1.25 to $3.00 in a research note on Wednesday, July 12th.
About DURECT Corporation
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.